{"id":"https://openalex.org/W7204887613","doi":"https://doi.org/10.26355/eurrev_202608_37910","title":"Trastuzumab deruxtecan plus pertuzumab as a substantial advancement in previously untreated patients with HER2-positive metastatic breast cancer.","display_name":"Trastuzumab deruxtecan plus pertuzumab as a substantial advancement in previously untreated patients with HER2-positive metastatic breast cancer.","publication_year":2026,"publication_date":"2026-08-01","ids":{"openalex":"https://openalex.org/W7204887613","doi":"https://doi.org/10.26355/eurrev_202608_37910","pmid":"https://pubmed.ncbi.nlm.nih.gov/42677694"},"language":"en","primary_location":{"id":"pmid:42677694","doi":"https://doi.org/10.26355/eurrev_202608_37910","is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42677694","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European review for medical and pharmacological sciences","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5018453933","display_name":"Andrea Messori","orcid":"https://orcid.org/0000-0002-5829-107X","observed_orcids":["https://orcid.org/0000-0002-5829-107X"]},"institutions":[{"id":"https://openalex.org/I4387153402","display_name":"Regione Toscana","ror":"https://ror.org/02r6c6d62","country_code":"IT","type":"government","lineage":["https://openalex.org/I4387153402"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"A Messori","raw_affiliation_strings":["Osservatorio Innovazione Regione Toscana, HTA Unit, Firenze, Italy. andrea.messori@osservatorioinnovazione.net"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Osservatorio Innovazione Regione Toscana, HTA Unit, Firenze, Italy. andrea.messori@osservatorioinnovazione.net","institution_ids":["https://openalex.org/I4387153402"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5137190552","display_name":"Tiziano Lupi","orcid":"https://orcid.org/0000-0002-4587-8736","observed_orcids":["https://orcid.org/0000-0002-4587-8736"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T Lupi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049350264","display_name":"Lorenzo Gasperoni","orcid":"https://orcid.org/0000-0001-6427-0809","observed_orcids":["https://orcid.org/0000-0001-6427-0809"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L Gasperoni","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5135545790","display_name":"Luna Del Bono","orcid":"https://orcid.org/0009-0007-8094-1677","observed_orcids":["https://orcid.org/0009-0007-8094-1677"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L Del Bono","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048378222","display_name":"Andrea Ossato","orcid":"https://orcid.org/0000-0001-8984-4733","observed_orcids":["https://orcid.org/0000-0001-8984-4733"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A Ossato","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5021999897","display_name":"Vera Damuzzo","orcid":"https://orcid.org/0000-0002-3685-6789","observed_orcids":["https://orcid.org/0000-0002-3685-6789"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"V Damuzzo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"30","issue":"8","first_page":"316","last_page":"326"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9940999746322632,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9940999746322632,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/trastuzumab-deruxtecan","display_name":"trastuzumab deruxtecan","score":0.9369999766349792},{"id":"https://openalex.org/keywords/pertuzumab","display_name":"pertuzumab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/her2-positive-metastatic-breast-cancer","display_name":"HER2-positive metastatic breast cancer","score":0.9919999837875366},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.8379999995231628},{"id":"https://openalex.org/keywords/indirect-comparison","display_name":"indirect comparison","score":0.6380000114440918},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8809999823570251},{"id":"https://openalex.org/keywords/emerald","display_name":"emerald","score":0.9419999718666077},{"id":"https://openalex.org/keywords/cleopatra","display_name":"Cleopatra","score":0.9990000128746033}],"concepts":[{"id":"https://openalex.org/C2781164504","wikidata":"https://www.wikidata.org/wiki/Q1998021","display_name":"Pertuzumab","level":5,"score":0.9732000231742859},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.9138000011444092},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8360999822616577},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.71670001745224},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6528000235557556},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.6517999768257141},{"id":"https://openalex.org/C2777511904","wikidata":"https://www.wikidata.org/wiki/Q425227","display_name":"Taxane","level":4,"score":0.6200000047683716},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.6177999973297119},{"id":"https://openalex.org/C2776387010","wikidata":"https://www.wikidata.org/wiki/Q408717","display_name":"Eribulin","level":5,"score":0.5073999762535095},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.44679999351501465},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.43160000443458557},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.4106999933719635},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.3986000120639801},{"id":"https://openalex.org/C2778087150","wikidata":"https://www.wikidata.org/wiki/Q3997863","display_name":"Trastuzumab emtansine","level":5,"score":0.3801000118255615},{"id":"https://openalex.org/C95190672","wikidata":"https://www.wikidata.org/wiki/Q815382","display_name":"Meta-analysis","level":2,"score":0.3634999990463257},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.34290000796318054},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.30790001153945923},{"id":"https://openalex.org/C10515644","wikidata":"https://www.wikidata.org/wiki/Q543310","display_name":"Survival analysis","level":2,"score":0.3073999881744385},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.2831000089645386},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.25609999895095825},{"id":"https://openalex.org/C82789193","wikidata":"https://www.wikidata.org/wiki/Q2142611","display_name":"Relative risk","level":3,"score":0.25360000133514404}],"mesh":[{"descriptor_ui":"D000068878","descriptor_name":"Trastuzumab","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000068878","descriptor_name":"Trastuzumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000095662","descriptor_name":"Polyether Polyketides","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D002166","descriptor_name":"Camptothecin","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018719","descriptor_name":"Erb-b2 Receptor Tyrosine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D018719","descriptor_name":"Erb-b2 Receptor Tyrosine Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D018796","descriptor_name":"Immunoconjugates","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":1,"locations":[{"id":"pmid:42677694","doi":"https://doi.org/10.26355/eurrev_202608_37910","is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42677694","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European review for medical and pharmacological sciences","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Systematic Review","id":"https://openalex.org/study-designs/systematic-review"},{"display_name":"Meta-Analysis","id":"https://openalex.org/study-designs/meta-analysis"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4205733538","https://openalex.org/W4416309288","https://openalex.org/W3202321862","https://openalex.org/W4411027200","https://openalex.org/W4221042474","https://openalex.org/W7166682105","https://openalex.org/W7214708685","https://openalex.org/W4206299960","https://openalex.org/W4408376190","https://openalex.org/W2621495365"],"abstract_inverted_index":{"OBJECTIVE:":[0],"First-line":[1],"treatment":[2],"of":[3,15,30,77,136,207,236],"HER2-positive":[4],"metastatic":[5],"breast":[6],"cancer":[7],"(HER2+MBC)":[8],"has":[9],"recently":[10],"evolved":[11],"with":[12,59,116,152,182,197],"the":[13,27,72,97,142,148,160,201,205,208,227],"introduction":[14],"trastuzumab":[16,137,172,221],"deruxtecan-based":[17],"regimens.":[18,150],"We":[19],"performed":[20],"an":[21],"indirect":[22],"comparative":[23],"analysis":[24],"to":[25,168,189],"evaluate":[26],"relative":[28],"efficacy":[29],"currently":[31,225],"available":[32],"first-line":[33,55,230],"treatments":[34],"using":[35,71,104],"reconstructed":[36,216],"individual":[37],"patient":[38],"data":[39,218],"(IPD).":[40],"MATERIALS":[41],"AND":[42],"METHODS:":[43],"A":[44],"systematic":[45],"PubMed":[46],"search":[47],"identified":[48],"phase":[49],"III":[50],"randomized":[51],"controlled":[52],"trials":[53,81],"evaluating":[54],"therapies":[56],"for":[57,232],"HER2+MBC":[58,233],"progression-free":[60],"survival":[61],"(PFS)":[62],"reported":[63,199],"through":[64],"Kaplan-Meier":[65],"curves.":[66,79],"Reconstructed":[67,191],"IPD":[68],"were":[69,82,102,130,194],"generated":[70],"IPDfromKM":[73,209],"method":[74],"after":[75],"digitization":[76],"published":[78],"Three":[80],"included:":[83],"DESTINY-Breast09,":[84],"EMERALD,":[85],"and":[86,110,126],"CLEOPATRA.":[87],"Trastuzumab":[88],"plus":[89,91,139,173,175,223],"pertuzumab":[90,140,174,224],"taxane":[92],"(THP)":[93],"was":[94],"adopted":[95],"as":[96,112],"common":[98],"comparator.":[99],"Treatment":[100],"effects":[101],"estimated":[103],"a":[105],"Cox":[106],"proportional":[107,127],"hazards":[108,128],"model":[109],"expressed":[111],"hazard":[113],"ratios":[114],"(HRs)":[115],"95%":[117,165,186],"confidence":[118],"intervals":[119],"(CIs).":[120],"Heterogeneity":[121],"across":[122],"pooled":[123,153],"control":[124],"groups":[125],"assumptions":[129],"also":[131],"assessed.":[132],"RESULTS:":[133],"The":[134],"combination":[135],"deruxtecan":[138,222],"demonstrated":[141],"most":[143,228],"favorable":[144],"PFS":[145,178],"profile":[146],"among":[147],"evaluated":[149],"Compared":[151],"THP":[154,183],"controls,":[155],"this":[156],"regimen":[157],"significantly":[158],"reduced":[159],"event":[161],"risk":[162],"(HR":[163,184],"0.49;":[164],"CI":[166,187],"0.40":[167],"0.60).":[169],"In":[170],"contrast,":[171],"eribulin":[176],"showed":[177],"outcomes":[179],"substantially":[180],"overlapping":[181],"0.96;":[185],"0.77":[188],"1.20).":[190],"HR":[192],"estimates":[193],"highly":[195],"consistent":[196],"those":[198],"in":[200,234],"original":[202],"trials,":[203],"confirming":[204],"reliability":[206],"approach.":[210],"CONCLUSIONS:":[211],"Indirect":[212],"comparisons":[213],"based":[214],"on":[215],"patient-level":[217],"suggest":[219],"that":[220],"represents":[226],"effective":[229],"strategy":[231],"terms":[235],"PFS.":[237]},"counts_by_year":[],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2026-09-02T00:00:00"}